Boehringer Ingelheim

News

Bayer trial combines two top drugs for kidney disease

Data from the CONFIDENCE trial shows the value of combining Bayer's Kerendia with an SGLT2 inhibitor to treat chronic kidney disease in diabetics.

Oncology

lady listening to audio on tablet device

Live from ASCO 2025: Boehringer Ingelheim on unmet needs and...

News

Boehringer advances oral therapy for geographic atrophy

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.

Market Access

Reuters Europe 2025: Collaboration key for innovation, BI he...

At Reuters Pharma Europe, Francesco Di Marco of Boehringer Ingelheim focused on the importance of innovating together.

Patients

Reuters pharmaUS 25 Brian Hilberdink Feature

New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an...

At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.

Market Access

Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA

Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.